Publication: Biomedical Chromatography
Abstract
Trigonella foenum-graecum (fenugreek) extract contains bioactive compounds effective for treating various conditions, but their pharmacokinetics in diabetic states had not been characterized. This study developed a validated UPLC-MS/MS method to simultaneously quantify trigonelline, 4-hydroxyisoleucine, and diosgenin, then applied it to compare their pharmacokinetics between normal and type 2 diabetic Wistar rats using non-compartmental analysis in Phoenix WinNonlin. The absorption rate of these bioactives increased while their distribution and elimination slowed in diabetic rats compared with normal rats. These findings suggest that diabetic status meaningfully alters the pharmacokinetics of fenugreek’s bioactive components, relevant to their therapeutic use in this population.
Author(s): Wadhwa G, Krishna KV, Taliyan R, Tandon N, Yadav SS, Banerjee D, Narwaria A, Katiyar C, Dubey SK
Published: November 16, 2021
Phoenix WinNonlin: PK in a Diabetic Model
Phoenix WinNonlin’s non-compartmental analysis showed diabetic status alters absorption and elimination of fenugreek’s bioactive components in this study. Paired with AI PK Reports, Phoenix WinNonlin can help turn an analysis into a complete PK document in minutes rather than days, within a Phoenix platform now available through Phoenix Cloud, combining cloud speed with AI-powered workflows.
